| Old Articles: <Older 6651-6660 Newer> |
|---|
 |
The Motley Fool
September 1, 2010
Brian Orelli |
Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge.   |
The Motley Fool
September 1, 2010
Seth Jayson |
Will Pharmaceutical Product Development Disappoint Analysts Next Quarter? There's no foolproof way to know the future for Pharmaceutical Product Development or any other company. |
The Motley Fool
September 1, 2010
Jordan DiPietro |
7 Sinking Health Care Stocks for Savvy Investors Check out these cheap health care stocks: Kendle International... LHC Group... Community Health Services... Almost Family... Universal Health Services... Medical Action Industries... GentivaHealth Services... |
Chemistry World
September 2010 |
Column: In the pipeline Derek Lowe considers the quandaries of living in the age of the kinase |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
The Motley Fool
August 31, 2010
Brian Orelli |
What Is Dendreon Worth? Now that's a good question, isn't it? |
The Motley Fool
August 31, 2010
Brian Orelli |
A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus. |
The Motley Fool
August 31, 2010
Jordan DiPietro |
7 Health-Care Stocks Getting Slammed These dividend-paying health care stocks could be good bargains. |
The Motley Fool
August 30, 2010
Brian Orelli |
Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition? |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
| <Older 6651-6660 Newer> Return to current articles. |
